{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:20:42Z","timestamp":1789075242381,"version":"build-2803163510"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"Importance<\/jats:title>Post\u2013COVID-19 condition (PCC), also known as long COVID, affects many individuals. Prevention of PCC is an urgent public health priority.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine whether treatment with nirmatrelvir in the acute phase of COVID-19 is associated with reduced risk of PCC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used the health care databases of the US Department of Veterans Affairs (VA) to identify patients who had a SARS-CoV-2 positive test result between January 3, 2022, and December 31, 2022, who were not hospitalized on the day of the positive test result, who had at least 1 risk factor for progression to severe COVID-19 illness, and who had survived the first 30 days after SARS-CoV-2 diagnosis. Those who were treated with oral nirmatrelvir within 5 days after the positive test (n\u2009=\u200935\u202f717) and those who received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection (control group, n\u2009=\u2009246\u202f076) were identified.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Treatment with nirmatrelvir or receipt of no COVID-19 antiviral or antibody treatment based on prescription records.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Inverse probability weighted survival models were used to estimate the association of nirmatrelvir (vs control) with post\u2013acute death, post\u2013acute hospitalization, and a prespecified panel of 13 post\u2013acute COVID-19 sequelae (components of PCC) and reported in relative scale as relative risk (RR) or hazard ratio (HR) and in absolute scale as absolute risk reduction in percentage at 180 days (ARR).<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 281\u202f793 patients (mean [SD] age, 61.99 [14.96]; 242\u202f383 [86.01%] male) who had a positive SARS-CoV-2 test result and had at least 1 risk factor for progression to severe COVID-19 illness were studied. Among them, 246\u202f076 received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection, and 35\u202f717 received oral nirmatrelvir within 5 days after the positive SARS-CoV-2 test result. Compared with the control group, nirmatrelvir was associated with reduced risk of PCC (RR, 0.74; 95% CI, 0.72-0.77; ARR, 4.51%; 95% CI, 4.01-4.99), including reduced risk of 10 of 13 post\u2013acute sequelae (components of PCC) in the cardiovascular system (dysrhythmia and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic system (neurocognitive impairment and dysautonomia), and shortness of breath. Nirmatrelvir was also associated with reduced risk of post\u2013acute death (HR, 0.53; 95% CI, 0.46-0.61); ARR, 0.65%; 95% CI, 0.54-0.77), and post\u2013acute hospitalization (HR, 0.76; 95% CI, 0.73-0.80; ARR, 1.72%; 95% CI, 1.42-2.01). Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that in people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease, treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of PCC across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection; the totality of findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post\u2013acute adverse health outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2023.0743","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T15:01:12Z","timestamp":1679583672000},"page":"554","source":"Crossref","is-referenced-by-count":296,"title":["Association of Treatment With Nirmatrelvir and the Risk of Post\u2013COVID-19 Condition"],"prefix":"10.1001","volume":"183","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri"},{"name":"Veterans Research and Education Foundation of St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri"},{"name":"Veterans Research and Education Foundation of St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyad","family":"Al-Aly","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri"},{"name":"Veterans Research and Education Foundation of St Louis, St Louis, Missouri"},{"name":"Department of Medicine, Washington University School of Medicine, St Louis, Missouri"},{"name":"Nephrology Section, Medicine Service, VA St Louis Health Care System, St Louis, Missouri"},{"name":"Institute for Public Health, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7862","key":"ioi230016r1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","article-title":"High-dimensional characterization of post-acute sequelae of COVID-19.","volume":"594","author":"Al-Aly","year":"2021","journal-title":"Nature"},{"issue":"7","key":"ioi230016r2","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","article-title":"Long COVID after breakthrough SARS-CoV-2 infection.","volume":"28","author":"Al-Aly","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"ioi230016r3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations.","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"6585","key":"ioi230016r4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The immunology and immunopathology of COVID-19.","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"issue":"7922","key":"ioi230016r5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/d41586-022-02140-w","article-title":"Long-COVID treatments: why the world is still waiting.","volume":"608","author":"Ledford","year":"2022","journal-title":"Nature"},{"issue":"15","key":"ioi230016r6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"ioi230016r7","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible\u2014the neighborhood atlas.","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med"},{"key":"ioi230016r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068414","article-title":"Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study.","volume":"376","author":"Cohen","year":"2022","journal-title":"BMJ"},{"issue":"21","key":"ioi230016r9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.15585\/mmwr.mm7121e1","article-title":"Post\u2013COVID conditions among adult COVID-19 survivors aged 18-64 and =65 years\u2014United States, March 2020-November 2021.","volume":"71","author":"Bull-Otterson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1098","key":"ioi230016r10","doi-asserted-by":"publisher","first-page":"n1098","DOI":"10.1136\/bmj.n1098","article-title":"Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study.","volume":"373","author":"Daugherty","year":"2021","journal-title":"BMJ"},{"issue":"693","key":"ioi230016r11","doi-asserted-by":"publisher","first-page":"n693","DOI":"10.1136\/bmj.n693","article-title":"Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study.","volume":"372","author":"Ayoubkhani","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"ioi230016r12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19.","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"ioi230016r13","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1038\/s41467-021-26513-3","article-title":"Burdens of post\u2013acute sequelae of COVID-19 by severity of acute infection, demographics and health status.","volume":"12","author":"Xie","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"ioi230016r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003773","article-title":"Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19.","volume":"18","author":"Taquet","year":"2021","journal-title":"PLoS Med"},{"issue":"11","key":"ioi230016r15","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1681\/ASN.2021060734","article-title":"Kidney outcomes in long COVID.","volume":"32","author":"Bowe","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ioi230016r16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068993","article-title":"Risks of mental health outcomes in people with COVID-19: cohort study.","volume":"376","author":"Xie","year":"2022","journal-title":"BMJ"},{"key":"ioi230016r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"5","key":"ioi230016r18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236?379 survivors of COVID-19: a retrospective cohort study using electronic health records.","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"ioi230016r19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S2213-8587(22)00044-4","article-title":"Risks and burdens of incident diabetes in long COVID: a cohort study.","volume":"10","author":"Xie","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"ioi230016r20","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/s41591-022-02001-z","article-title":"Long-term neurologic outcomes of COVID-19.","volume":"28","author":"Xu","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"ioi230016r21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2213-8587(22)00355-2","article-title":"Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.","volume":"11","author":"Xu","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"983","key":"ioi230016r22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36223-7","article-title":"Long-term gastrointestinal outcomes of COVID-19.","volume":"14","author":"Xu","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"ioi230016r23","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/s41591-022-02051-3","article-title":"Acute and postacute sequelae associated with SARS-CoV-2 reinfection.","volume":"28","author":"Bowe","year":"2022","journal-title":"Nat Med"},{"issue":"16","key":"ioi230016r24","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","article-title":"Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021.","volume":"328","author":"Wulf Hanson","year":"2022","journal-title":"JAMA"},{"key":"ioi230016r25","doi-asserted-by":"publisher","first-page":"m4677","DOI":"10.1136\/bmj.m4677","article-title":"Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with COVID-19 and seasonal influenza: cohort study.","volume":"371","author":"Xie","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"ioi230016r26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2215\/CJN.09610620","article-title":"Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19.","volume":"16","author":"Bowe","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"ioi230016r27","article-title":"Molnupiravir and risk of hospitalization or death: a target trial emulation using the US Veterans Affairs healthcare databases.","volume":"380","author":"Xie","year":"2023","journal-title":"BMJ"},{"issue":"1","key":"ioi230016r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41581-022-00652-2","article-title":"Long COVID: long-term health outcomes and implications for policy and research.","volume":"19","author":"Al-Aly","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"ioi230016r29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-8587(22)00324-2","article-title":"Diabetes after SARS-CoV-2 infection.","volume":"11","author":"Al-Aly","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7944","key":"ioi230016r30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2802878\/jamainternal_xie_2023_oi_230016_1705014761.97741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T16:03:39Z","timestamp":1705421019000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2802878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2023.0743","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}